Press Releases SinoMab BioScience Limited

Equities

3681

HK0000544194

Delayed Hong Kong S.E. Other stock markets 23:40:15 2024-05-08 EDT			5-day change	1st Jan Change
1.87 ^HKD	+2.75%		-1.58%	+11.31%

03-25	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
02-07	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy	04-16	AQ
SinoMab's IND Application of SM17 has once again Received Approval from NAMP	23-09-11	AQ
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP	23-08-14	AQ
SinoMab Annouces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE	23-05-21	AQ
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards"	22-12-19	AQ
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company	22-11-04	AQ
Everest Medicines Receives Approval of Investigational New Drug Application from China NMPA for EVER001, a Novel BTK Inhibitor in Development for Treatment of Renal Diseases	22-09-27	AQ
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA	22-08-23	AQ
SinoMab Received the Highest Subsidy from HKSTP	22-07-08	AQ
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S.	22-06-21	AQ
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.	22-06-15	AQ
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE	22-06-09	AQ
SinoMab Announces IND APPLICATION FOR SN1011 APPROVED BY NMPA	22-04-20	AQ
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA	22-03-14	AQ
SinoMab BioScience : DATE OF BOARD MEETING	22-03-09	PU
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA	22-02-17	AQ
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE	22-02-07	AQ
SinoMab Awared the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies"	22-01-11	AQ
SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03	21-11-30	AQ
SinoMab Was Invited to Attend the Inaugural Asia Summit on Global Health	21-11-26	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SinoMab BioScience Limited

Equities

3681

HK0000544194

Press Releases

Filters